Replies to post #43289 on Biotech Values

[genisi]

>provided that production cost for the recombinants is low enough<

I think (and hope) that recombinant are cheaper because they do not rely on blood donation however, If OMRI,KAMADA and alike are clever, they can compete by discounting their product considerably.